MPLA is a TLR4 agonist (extracted from Salmonella Minnesota), binds to TLR4-MD2, and has been used as a vaccine adjuvant against cervical cancer and hepatitis B [86]. This evidence concerns the gene TLR4 and cervical carcinoma.